Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Alcon - Wikipedia

    en.wikipedia.org/wiki/Alcon

    Novartis bought 52% stake from Nestlé for $28.1 Billion. This deal brought the total ownership of Alcon by Novartis to 77%. Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon.

  3. Novartis Completes Purchase of Alcon Majority Stake ... - AOL

    www.aol.com/news/2010-08-26-novartis-alcon-buy...

    The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.

  4. Novartis - Wikipedia

    en.wikipedia.org/wiki/Novartis

    Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...

  5. Novartis Aims to Beat $1.9B in Cost Savings By Year's End - AOL

    www.aol.com/2011/09/13/novartis-aims-to-beat-19b...

    Novartis (NYS: NVS) has two things to say. It now expects more bang for its buck from Alcon. The eye-care acquisition, which cost Novartis $51 billion, will deliver high single-digit to low double ...

  6. Bausch & Lomb - Wikipedia

    en.wikipedia.org/wiki/Bausch_&_Lomb

    Bausch & Lomb (since 2010 stylized as Bausch + Lomb [2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [4] [5] The company was founded in Rochester ...

  7. Novartis signs gene therapy deal with Voyager for $100 ... - AOL

    www.aol.com/news/novartis-signs-gene-therapy...

    (Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.

  8. Nepafenac - Wikipedia

    en.wikipedia.org/wiki/Nepafenac

    Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. [3] Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 ...

  9. Shop our favorite deals under $50 from Nordstrom's ... - AOL

    www.aol.com/lifestyle/shop-our-favorite-deals...

    The Nordstrom Anniversary Sale is in full swing and if you haven't shopped yet, there's still time. We combed through more than 5,000 items to find you the best deals under $50 — we're talking ...